CARB-X is investing up to $11m into US-based Microbion to develop its inhaled drug pravibismane to treat cystic fibrosis. CARB-X is awarding Microbion Corporation…
CARB-X funds US-based Facile Therapeutics to further develop a new oral drug that would disable toxins that enable C. difficile infections to recur. CARB-X…
CARB-X will support US-based Day Zero Diagnostics with $6.2M. The company combines whole-genome sequencing and machine learning to identify a pathogen and its drug-resistance…
As part of a large initiative to combat COVID-19 and future health pandemics WHO and EIB also joined forces on a new financing initiative…